Practitioners doubt the efficacy of hydroxychloroquine for COVID-19
Category: #health  By Mateen Dalal  Date: 2020-04-23
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Practitioners doubt the efficacy of hydroxychloroquine for COVID-19

As the debate on hydroxychloroquine’s effectiveness over COVID-19 intensifies, a significant number of physicians across the globe still presume that patients should consume the drug to treat the symptoms of COVID-19.

However, the anti-malaria drug, which was termed as the game-changing drug in this epidemic by President Trump, has recently failed to show any benefit on a patient admitted in Veterans Health Administration medical facilities.

According to an analysis, the two primary outcomes of hydroxychloroquine when tested on COVID-19 patients was death and the requirement for mechanical ventilation.

Evidently, this analysis was steered retrospectively on the basis of data from confirmed coronavirus patients hospitalized in every Veterans Health Administration medical facility. Apparently, the study examined just 368 patients but established a base conclusion from the collective outcomes of COVID-19 patients treated with hydroxychloroquine.

Hydroxychloroquine has now become the most demanded drug across the world, even though there is no strong evidence to support the claims that it can benefit COVID-19 patients. This has created a supply gap for both azithromycin and hydroxychloroquine.

Currently, there are numerous prospective, randomized studies of hydroxychloroquine that could help medical practitioners to gain an understanding on the effects and benefits of these drugs in COVID-19 patients and would eventually offer key information about the efficacy and safety of the drug.

As per a survey conducted by healthcare data collection firm, Sermo, almost one-quarter (i.e. 5,158) of over 20,000 physicians worldwide think that the anti-malarial drug would be useful against the coronavirus infections. However, the evidence on the medical benefits of hydroxychloroquine hasn’t been peer-reviewed yet.

For now, many hospitals are prescribing the drug to COVID-19 patients with a hope that it shows a drastic improvement in patient health despite any evidence over its effectiveness.

Source Credit: https://thehill.com/policy/healthcare/493931-largest-analysis-of-hydroxychloroquine-use-finds-no-benefit-increased

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Chevrolet Camaro could be replaced by a potential all-electric sedan

Chevrolet Camaro could be replaced by a potential all-electric sedan

By Mateen Dalal

Reportedly, General Motors Company is planning to replace the Chevrolet Camaro with an all-electric performance sedan in a few years with the existing model likely to be phased out by 2024. There have many reports about discontinuing the Camaro&rsqu...

Sequoia India launches Spark Fellowship to support female entrepreneurs

Sequoia India launches Spark Fellowship to support female entrepreneurs

By Mateen Dalal

The Spark fellowship program is for women entrepreneurs in India and Southeast Asia. The year-long program is aimed at bringing more gender diversity and supporting startups led by women. Sequoia Capital has recently revealed the launch of a yea...

Biden names avid tech critic Jonathan Kanter as DOJ antitrust chief

Biden names avid tech critic Jonathan Kanter as DOJ antitrust chief

By Mateen Dalal

U.S. President Joe Biden will reportedly nominate Jonathan Kanter, a competition lawyer, and fervid Google critic, to head the antitrust division of the Justice Department. Kanter has been actively representing several companies in competition cases...